DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Kaufman PA, Awada A, Twelves C et al.
A Phase III, open-label, randomized, multicenter study of eribulin mesylate
versus capecitabine in patients with locally advanced or metastatic breast
cancer previously treated with anthracyclines and taxanes.
Cancer Res 2012;
72 (Suppl. 24) 109s
We do not assume any responsibility for the contents of the web pages of other providers.